20 articles
Researchers find that combining Ganoderma lucidum and Sanghuangporus vaninii extracts may fight colorectal cancer through vitamin D and Wnt pathways.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-ฮณ/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
Adding an autophagy inhibitor to anlotinib plus PD-1 blockade dramatically reshapes the tumor microenvironment in NSCLC models.
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
New research reveals how RBM39 protein enhances DNA repair in liver cancer cells, suggesting combination therapy targets.
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Metabolite supplement protects heart from chemo toxicity and enhances tumor suppression in breakthrough dual-action study.
A comprehensive review reveals how iron-driven cell death can be exploited to treat ATC, one of the most lethal human cancers.
Study identifies senescent EGR1+ B cells that sabotage immunotherapy in esophageal cancer, with fisetin showing promise as a therapeutic enhancer.
A large French cohort study reveals conjugated bile acids raise breast cancer risk while vitamin K intake may be protective via metabolic pathways.
Novel treatment triggers ferroptosis in cancer cells while activating immune responses that further enhance cancer cell death.
Engineered green tea compound nanoparticles activate cellular powerhouses to suppress tumor growth and improve immune response against melanoma.
